11/17/2026 | Press release | Distributed by Public on 11/17/2026 14:46
Team RMB,
I want to share an important company update with all of you. As announced in a public press release earlier today, Rapid Micro Biosystems, Inc. ("Rapid Micro") has signed a definitive merger agreement under which Merck KGaA, Darmstadt, Germany will acquire all outstanding shares of the Company.
This marks an important milestone in the evolution of Rapid Micro and creates new opportunities to expand the impact of our technology, our customers, and our team. I'm incredibly proud of what the Rapid Micro team has accomplished and the transformative impact of the Growth Direct platform on pharmaceutical manufacturing. Over the past 18 months, we have built a strong partnership with Millipore S.A.S., a subsidiary of the Life Science business of Merck KGaA, Darmstadt, Germany centered on a shared commitment to innovation and helping customers modernize quality control workflows. Rapid Micro has established the Growth Direct platform as a leading solution for automating microbial quality control, with most of the world's top pharmaceutical manufacturers as customers. As part of the Life Science business of Merck KGaA, Darmstadt, Germany, we expect to significantly expand the reach of the Growth Direct platform and more fully serve our combined global customer base.
We believe this transaction reflects the strength of our technology, our world-class customer base, and most importantly the dedication, expertise, and quality of our employees.
While this announcement represents an exciting step forward, the transaction is not expected to close until December 2026, subject to customary closing conditions. Until then, Rapid Micro and Merck KGaA, Darmstadt, Germany remain separate companies, and our focus should remain on serving our customers and delivering against our commitments.
You should be proud of what we have built together. Through your dedication and hard work, we have established Growth Direct as a leading global platform for automating microbial quality control and earned the trust of many of the world's leading pharmaceutical manufacturers. As part of Merck KGaA, Darmstadt, Germany's Life Science business, we will have the resources and global reach to expand that impact even further.
You will receive a meeting invitation for a special Town Hall meeting today at 11:00 a.m. ET in Lowell where we will discuss these announcements in further detail and answer your questions. For all local employees, please plan to join us in person.
Thank you all for your unwavering dedication and commitment to our company and our customers.
Best,
Rob
Additional Information and Where to Find It
The tender offer described in this communication has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo II, Inc. ("Purchaser") will file a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (the "SEC"), and Rapid Micro Biosystems ("Rapid") will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC. INVESTORS AND SECURITY HOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) THAT WILL BE FILED BY MERCK KGAA, DARMSTADT, GERMANY AND PURCHASER WITH THE SEC AND THE RELATED SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY RAPID WITH THE SEC, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These materials (once they become available) will be made available to Rapid shareholders at no cost by the information agent for the tender offer. Once filed, these documents will be available at no charge on the SEC's website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge from Merck KGaA, Darmstadt, Germany under the "Investors" section of Merck KGaA Darmstadt, Germany's website at https://www.emdgroup.com/en. A copy of the solicitation/recommendation statement (once it becomes available) also may be obtained free of charge from Rapid under the "Investor Relations" section of Rapid's website at https://www.rapidmicrobio.com/.